Krista M Isaac
Overview
Explore the profile of Krista M Isaac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rezazadeh A, Szabo A, Khurana A, Inwards D, Lunning M, Bartlett N, et al.
Haematologica
. 2023 Oct;
109(5):1439-1444.
PMID: 37855051
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT...
2.
Jayappa K, Tran B, Gordon V, Morris C, Saha S, Farrington C, et al.
J Clin Invest
. 2023 May;
133(13).
PMID: 37166997
Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic...
3.
Sawalha Y, Goyal S, Switchenko J, Romancik J, Kamdar M, Greenwell I, et al.
Blood Adv
. 2023 Feb;
7(13):2983-2993.
PMID: 36809796
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n = 50, 62%) or in combination with...
4.
Jayappa K, Gordon V, Morris C, Wilson B, Shetty B, Cios K, et al.
Blood Adv
. 2021 Aug;
5(17):3497-3510.
PMID: 34432864
The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts...
5.
Roeker L, Eyre T, Thompson M, Lamanna N, Coltoff A, Davids M, et al.
Blood
. 2021 Jul;
138(18):1768-1773.
PMID: 34297826
No abstract available.
6.
Isaac K, Portell C, Williams M
Curr Oncol Rep
. 2021 Jul;
23(9):102.
PMID: 34269910
Purpose Of Review: This review summarizes the unique presentation and management of the leukemic variant of mantle cell lymphoma (LV-MCL, also referred to as non-nodal MCL) and highlights the biologic...
7.
Isaac K, Reed D, Desai R, Williams E, Balkrishnan R, Keng M, et al.
Cancer Rep (Hoboken)
. 2021 Mar;
4(4):e1354.
PMID: 33751859
Background: Acute myeloid leukemia, the most common acute leukemia in adults, has a poor overall survival. Studies have suggested that certain socioeconomic factors such as living in a rural or...
8.
Mato A, Roeker L, Lamanna N, Allan J, Leslie L, Pagel J, et al.
Blood
. 2020 Jul;
136(10):1134-1143.
PMID: 32688395
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust...
9.
Mato A, Roeker L, Jacobs R, Hill B, Lamanna N, Brander D, et al.
Clin Cancer Res
. 2020 Mar;
26(14):3589-3596.
PMID: 32198151
Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental Design: To address this,...
10.
Nguyen M, Isaac K, Dougherty R
J Community Hosp Intern Med Perspect
. 2016 Sep;
6(4):32129.
PMID: 27609727
Gastrointestinal perforations are a complication of 2-10% of duodenal ulcers. There are a variety of etiologies associated with duodenal ulcer formation and its complications. Corticosteroid use is associated with an...